Pablo Sardi

Dr. Pablo Sardi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PSPablo Sardi
Pablo Sardi
CVCatherine Viel
Catherine Viel
JCJennifer Clarke
Jennifer Clarke
CTChristopher M. Treleaven
Christopher M. Treleaven
ARAmy M. Richards
Amy M. Richards
LSLamya S. Shihabuddin
Lamya S. Shihabuddin
Significance: Mutations in the glucocerebrosidase gene ( GBA ) represent the most common genetic risk factor for Parkinson’s disease (PD), affecting 5–10% of patients and accelerating disease progression. Mutations in GBA and consequent loss of enzymatic activity allow glucocerebrosides to build up in cells. Here, we tested an experimental drug that inhibits the production of glucocerebrosides, hypothesizing that producing fewer lipids may counteract the challenge of clearing them from cells. In mice with mutant Gba , prolonged administration of this inhibitor reduced brain glucocerebrosides. In addition, this treatment reduced levels of aggregated α-synuclein, a protein that builds up in PD brains, and improved behavioral responses. The findings suggest that reducing glucocerebrosides might represent a viable therapeutic strategy for PD patients carrying GBA mutations.

27 April 2018 in Movement Disorders
Verified
Journal Article
Open access
PDF file
PSPablo Sardi
Pablo Sardi
JCJesse M. Cedarbaum
Jesse M. Cedarbaum
PBPatrik Brundin
Patrik Brundin
The greatest unmet medical need in Parkinson's disease (PD) is treatments that slow the relentless progression of symptoms. The discovery of genetic variants causing and/or increasing the risk for PD has provided the field with a new arsenal of potential therapies ready to be tested in clinical trials. We highlight 3 of the genetic discoveries (α‐synuclein, glucocerebrosidase, and leucine‐rich repeat kinase) that have prompted new therapeutic approaches now entering the clinical stages. We are at an exciting juncture in the journey to developing disease‐modifying treatments based on knowledge of PD genetics and pathology. This review focuses on therapeutic paradigms that are under clinical development and highlights a wide range of key outstanding questions in PD. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

12 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMelissa S. Rotunno
Melissa S. Rotunno
MLMonica Lane
Monica Lane
WZWenfei Zhang
Wenfei Zhang
PWPavlina Wolf
Pavlina Wolf
POPetra Oliva
Petra Oliva
PSPablo Sardi
Pablo Sardi
Parkinson’s disease, the most common age-related movement disorder, is a progressive neurodegenerative disease with unclear etiology. Better understanding of the underlying disease mechanism(s) is an urgent need for the development of disease-modifying therapeutics. Limited studies have been performed in large patient cohorts to identify protein alterations in cerebrospinal fluid (CSF), a proximal site to pathology. We set out to identify disease-relevant protein changes in CSF to gain insights into the etiology of Parkinson’s disease and potentially assist in disease biomarker identification. In this study, we used liquid chromatography-tandem mass spectrometry in data-independent acquisition (DIA) mode to identify Parkinson’s-relevant biomarkers in cerebrospinal fluid. We quantified 341 protein groups in two independent cohorts (n = 196) and a longitudinal cohort (n = 105 samples, representing 40 patients) consisting of Parkinson’s disease and healthy control samples from three different sources. A first cohort of 53 Parkinson’s disease and 72 control samples was analyzed, identifying 53 proteins with significant changes (p < 0.05) in Parkinson’s disease relative to healthy control. We established a biomarker signature and multiple protein ratios that differentiate Parkinson’s disease from healthy controls and validated these results in an independent cohort. The second cohort included 28 Parkinson’s disease and 43 control samples. Independent analysis of these samples identified 41 proteins with significant changes. Evaluation of the overlapping changes between the two cohorts identified 13 proteins with consistent and significant changes (p < 0.05). Importantly, we found the extended granin family proteins as reduced in disease, suggesting a potential common mechanism for the biological reduction in monoamine neurotransmission in Parkinson’s patients. Our study identifies several novel protein changes in Parkinson’s disease cerebrospinal fluid that may be exploited for understanding etiology of disease and for biomarker development.

31 October 2022 in The EMBO Journal
Verified
Journal Article
Closed access
FCFelipe Cabral‐Miranda
Felipe Cabral‐Miranda
GTGiovanni Tamburini
Giovanni Tamburini
GMGabriela Martinez
Gabriela Martinez
Alvaro O. ArdilesAlvaro O. Ardiles
Alvaro O. Ardiles
DMDanilo B Medinas
Danilo B Medinas
CHClaudio A. Hetz
Claudio A. Hetz

13 October 2020 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JDJames C. Dodge
James C. Dodge
EJElizabeth H. Jensen
Elizabeth H. Jensen
JYJinlong Yu
Jinlong Yu
PSPablo Sardi
Pablo Sardi
ABAllison R. Bialas
Allison R. Bialas
LSLamya S. Shihabuddin
Lamya S. Shihabuddin
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease characterized by motor neuron (MN) death. Lipid dysregulation manifests during disease; however, it is unclear whether lipid homeostasis is adversely affected in the in the spinal cord gray matter (GM), and if so, whether it is because of an aberrant increase in lipid synthesis. Moreover, it is unknown whether lipid dysregulation contributes to MN death. Here, we show that cholesterol ester (CE) and triacylglycerol levels are elevated several-fold in the spinal cord GM of male sporadic ALS patients. Interestingly, HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, was reduced in the spinal cord GM of ALS patients. Increased cytosolic phospholipase A2 activity and lyso-phosphatidylcholine (Lyso-PC) levels in ALS patients suggest that CE accumulation was driven by acyl group transfer from PC to cholesterol. Notably, Lyso-PC, a byproduct of CE synthesis, was toxic to human MNsin vitro. Elevations in CE, triacylglycerol, and Lyso-PC were also found in the spinal cord of SOD1G93Amice, a model of ALS. Similar to ALS patients, a compensatory downregulation of cholesterol synthesis occurred in the spinal cord of SOD1G93Amice; levels of sterol regulatory element binding protein 2, a transcriptional regulator of cholesterol synthesis, progressively declined. Remarkably, overexpressing sterol regulatory element binding protein 2 in the spinal cord of normal mice to model CE accumulation led to ALS-like lipid pathology, MN death, astrogliosis, paralysis, and reduced survival. Thus, spinal cord lipid dysregulation in ALS likely contributes to neurodegeneration and developing therapies to restore lipid homeostasis may lead to a treatment for ALS.SIGNIFICANCE STATEMENTNeurons that control muscular function progressively degenerate in patients with amyotrophic lateral sclerosis (ALS). Lipid dysregulation is a feature of ALS; however, it is unclear whether disrupted lipid homeostasis (i.e., lipid cacostasis) occurs proximal to degenerating neurons in the spinal cord, what causes it, and whether it contributes to neurodegeneration. Here we show that lipid cacostasis occurs in the spinal cord gray matter of ALS patients. Lipid accumulation was not associated with an aberrant increase in synthesis or reduced hydrolysis, as enzymatic and transcriptional regulators of lipid synthesis were downregulated during disease. Last, we demonstrated that genetic induction of lipid cacostasis in the CNS of normal mice was associated with ALS-like lipid pathology, astrogliosis, neurodegeneration, and clinical features of ALS.

31 October 2018 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LSLamya S. Shihabuddin
Lamya S. Shihabuddin
PBPatrik Brundin
Patrik Brundin
JGJ. Timothy Greenamyre
J. Timothy Greenamyre
DSDiane Stephenson
Diane Stephenson
PSPablo Sardi
Pablo Sardi
The greatest unmet therapeutic need in Parkinson's disease (PD) is a treatment that slows the relentless progression of the symptoms and the neurodegenerative process. This review highlights the utility of genetics to understand the pathogenic mechanisms and develop novel therapeutic approaches for PD. The focus is on strategies provided by genetic studies: notably via the reduction and clearance of α-synuclein, inhibition of LRRK2 kinase activity, and modulation of glucocerebrosidase-related substrates. In addition, the critical role of precompetitive public-private partnerships in supporting trial design optimization, overall drug development, and regulatory approvals is illustrated. With these great advances, the promise of developing transformative therapies that halt or slow disease progression is a tangible goal.